1. health and fitness
2. disease

CME-CERTIFIEDDINNERSYMPOSIUM
2.0
Effective Disease Management of
ULCERATIVE COLITIS
Where Are We Now and What Does the Future Hold?
Sunday, May 17, 2015
Marrio Marquis Washington, DC
Marquis Ballroom – Salon 6 • Meeting Level 2
6:00 pm – 6:30 pm
6:30 pm – 8:30 pm
Registration and Dinner
CME-certified Activity
ActivityChair
Faculty
Gary R. Lichtenstein, MD
Silvio Danese, MD, PhD
Bruce E. Sands, MD, MS
Douglas C. Wolf, MD
REGISTER ONLINE! VindicoCME.com/051715
This continuing medical education activity is provided by
VINDICO
medical education
This activity is supported by an educational grant from
Receptos, Inc.
®
This program is not affiliated with Digestive Disease Week .
OVERVIEW
Ulcerative colitis (UC) is the most common inflammatory
bowel disease (IBD) worldwide, with approximately 600,000
Americans living with UC. Ulcerative colitis is characterized by an
overactive immune response to the gut enteric flora, resulting in
bowel inflammation and ulceration. As one study demonstrated
that approximately 80% of studied patients with IBD received
suboptimal therapy, there is substantial room for improvement
in the care of patients with IBD. Several agents with a variety of
mechanisms of action are now in clinical development or available
for the treatment of UC. As the therapeutic landscape for UC
continues to evolve, physicians need to be aware of how these
agents can be used to optimize outcomes for patients. This CME
activity addresses the mechanisms of action, efficacy, safety, and
recommended usage of available and emerging therapies for the
management of moderate-to-severe UC. Preclinical and clinical
data on novel immunomodulators for UC will be discussed.
LEARNINGOBJECTIVES
Upon successful completion of this educational activity,
participants should be beer able to:
•
Review the mechanisms of action of available and
emerging therapeutic agents for the management of
moderate-to-severe UC.
•
Evaluate the preclinical and clinical data regarding the
safety and efficacy of new and emerging therapeutic
agents for the management of moderate-to-severe UC.
•
Differentiate available and emerging therapies for the
management of moderate-to-severe UC based on
mechanism of action, safety, efficacy, and administration.
TARGETAUDIENCE
The intended audience for this activity is gastroenterologists
and other health care professionals involved in the treatment
of patients with ulcerative colitis.
REGISTER ONLINE! VindicoCME.com/051715
AGENDA
6:30 pm — 6:35 pm
Introduction and Pretest
Gary R. Lichtenstein, MD
6:35 pm — 6:55 pm
Effective Management of
Moderate-to-Severe Ulcerative Colitis –
The Current State of the Union
Douglas C. Wolf, MD
6:55 pm — 7:00 pm
Question and Answer
7:00 pm — 7:25 pm
Ulcerative Colitis: Mechanisms of
Action of Novel Pharmacologic Agents
in Development
Silvio Danese, MD, PhD
7:25 pm — 7:30 pm
Question and Answer
7:30 pm — 7:55 pm
Examining Novel Therapies for Disease
Management – A Clinical Review of the
Newly Released Data
Bruce E. Sands, MD, MS
7:55 pm — 8:00 pm
Question and Answer
8:00 pm — 8:05 pm
Posest
Gary R. Lichtenstein, MD
8:05 pm — 8:20 pm
Panel Discussion – Clinical and Practical
Considerations in UC Management
Moderated by Gary R. Lichtenstein, MD
8:20 pm — 8:30 pm
Question and Answer
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education
to provide continuing medical education for physicians.
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for
Commercial Support, all planners, teachers, and authors involved in the development of CME content
are required to disclose to the accredited provider their relevant financial relationships. Relevant
financial relationships will be disclosed to the activity audience.
Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping
is prohibited without written permission from the program committee.
REGISTER ONLINE! VindicoCME.com/051715
© 2015 Shutterstock.com/Sebastian Kaulitzki
Vindico Medical Education designates this live activity for a maximum of 2.0 AMA PRA Category
1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their
participation in the activity.
ACTIVITYCHAIR
Gary R. Lichtenstein, MD, FACP, FACG, AGAF
Professor of Medicine
Raymond and Ruth Perelman
School of Medicine of the University of Pennsylvania
Director, Center for Inflammatory Bowel Disease
University of Pennsylvania
Philadelphia, PA
FACULTY
Silvio Danese, MD, PhD
Head, IBD Center
Department of Gastroenterology
Istituto Clinico Humanitas
Milan, Italy
Bruce E. Sands, MD, MS
Chief, Dr. Henry D. Janowitz Division of Gastroenterology
Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai
Mount Sinai Health System
New York, NY
Douglas C. Wolf, MD
Director, IBD Center
Atlanta Gastroenterology Associates
Atlanta, GA
REGISTER ONLINE! VindicoCME.com/051715
CME-CERTIFIEDDINNERSYMPOSIUM
Effective Disease Management of
2.0
ULCERATIVE COLITIS
Where Are We Now and What Does the Future Hold?
Sunday, May 17, 2015
Marrio Marquis Washington, DC
Marquis Ballroom – Salon 6
Meeting Level 2
6:00 pm – 6:30 pm
Registration and Dinner
6:30 pm – 8:30 pm
CME-certified Activity
Register Online Today!
VindicoCME.com/051715
Contact Information:
Pre-registration is encouraged but not required.
Seating to be based on arrival order;
early arrival is recommended.
E-mail:
[email protected]
Toll-free: 877-307-5225, ext. 219 or 476
Phone:
856-994-9400, ext. 219 or 476
Fax:
856-251-0278
Mail:
Registration Department
6900 Grove Road
Thorofare, NJ 08086-9447
First Name ______________________________ M.I._______ Last Name _________________________________________
Preferred Mailing Address (Home/Business) ___________________________________________________________________
______________________________________________________________________________________________________
City___________________________
State_______ Zip Code ______________ Country ____________________________
Daytime Phone_______________________________________ Evening Phone ______________________________________
Fax ____________________________ E-mail ______________________________________ Date of Birth _______________
(for confirmation purposes)
(for tracking credits ONLY)
(for confirmation purposes)
National Provider Identifier (NPI)_______________ Medical License Number______________ Medical License State____________
Degree (please specify)
❑ MD/DO
❑ PhD
❑ MD, PhD
❑ PharmD/RPh
❑ PA
❑ RN/BSN/MSN
❑ NP
❑ Industry
❑ Other:_______
How did you hear about this meeting?
(multiple selections allowed)
❑ Advertisement
❑ Brochure
❑ E-mail
❑ Postcard
❑ Web site
❑ Word of mouth
Specialty (select one)
❑ Gastroenterology
❑ Hepatology
❑ Internal Medicine
❑ Family Practice/General Practice
❑ Other_______________
CME Activity Request
❑ YES, I would like to receive information regarding future
CME activities related to this therapeutic area.
ADA compliance: In compliance with the Americans with Disabilities
Act of 1990, we will make reasonable efforts to accommodate
persons with disabilities. Please call with your requests.
Priority Code: 668 - 1 2 3
6900 Grove Road • Building 100
Thorofare, NJ 08086-9447
Presorted
First Class Mail
US Postage
PAID
Permit # 906
Bellmawr NJ
CME-CERTIFIEDDINNERSYMPOSIUM
Effective Disease Management of
ULCERATIVE COLITIS
2.0
Where Are We Now and What Does the Future Hold?
Sunday, May 17, 2015
Marrio Marquis Washington, DC
Marquis Ballroom – Salon 6
Meetingg Level 2
6:00 pm – 6:30 pm
Registration and Dinner
6:30 pm – 8:30 pm
CME-certified Activity
REGISTER ONLINE! VindicoCME.com/051715